Translating cancer 'omics' to improved outcomes.
The genomics era has yielded great advances in the understanding of cancer biology. At the same time, the immense complexity of the cancer genome has been revealed, as well as a striking heterogeneity at the whole-genome (or omics) level that exists between even histologically similar tumors. The vast accrual and public availability of multi-omics databases with associated clinical annotation including tumor histology, patient response, and outcome are a rich resource that has the potential to lead to rapid translation of high-throughput omics to improved overall survival. We focus on the unique advantages of a multidimensional approach to genomic analysis in this new high-throughput omics age and discuss the implications of the changing cancer demographic to translational omics research.
British Columbia Cancer Research Centre, Vancouver V5Z 1L3, Canada. evucic@bccrc.ca
Emily A
EA
Vucic
Kelsie L
KL
Thu
Keith
K
Robison
Leszek A
LA
Rybaczyk
Raj
R
Chari
Carlos E
CE
Alvarez
Wan L
WL
Lam
D000818:Animals; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism; D004195:Disease Models, Animal; D055088:Early Detection of Cancer; D056726:Genetic Association Studies; D023281:Genomics; D006801:Humans; D058990:Molecular Targeted Therapy; D009154:Mutation; D009369:Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000628:therapy*; D011379:Prognosis; D040901:Proteomics; D015398:Signal Transduction; D057170:Translational Research, Biomedical
D014408:Biomarkers, Tumor